

## **TRIMEDYNE'S CHAIRMAN INTERVIEWED BY THE WALL STREET TRANSCRIPT**

FOR IMMEDIATE RELEASE

CONTACT: Jeff Rudner  
(949) 206-1007, Ext. 2285  
jrudner@trimedyne.com

July 24, 2006. – Lake Forest, CA: TRIMEDYNE, INC. (OTCBB "TMED") today announced its Chairman, Marvin P. Loeb, was interviewed by The Wall Street Transcript. The interview will appear in the July 24, 2006 issue of the Wall Street Transcript and will be available FREE online at <http://www.twst.com/ceos.htm>.

Dr. Loeb discussed Trimedyne's new side firing laser device, which Trimedyne recently announced will be marketed by Boston Scientific Corporation (NYSE "BSX") in the United States and by Lumenis, Ltd. throughout the rest of the world for use in conjunction with Lumenis' Holmium Lasers for holmium laser ablation of the prostate (HoLAP) in men. Mr. Loeb also provided an overview of Trimedyne's business and the large market opportunity presented by this new device.

The outpatient HoLAP procedure has the potential to replace conventional surgical procedures to treat an enlarged prostate, which entail hospitalization, significant bleeding and the risk of a blood transfusion, impotence and incontinence. The interview also covers Trimedyne's outpatient laser procedures to treat herniated or ruptured spinal discs, which also have the potential to replace conventional surgery, presenting another large market opportunity.

Commenting on the interview, Mr. Loeb said, "We are pleased that The Wall Street Transcript has chosen to feature Trimedyne in its new July 24 issue and on their website. We are gratified by the increased attention being paid to Trimedyne's new laser products and their market potential.

To access the interview without charge, go to <http://twst.com/ceos.htm>. It will be archived and periodically updated. For a copy of the July 24 Issue or information on subscribing to The Wall Street Transcript, call 800-426-7673.

Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. Trimedyne has an extensive portfolio of patents covering side-firing technologies. For product, financial and other information, visit Trimedyne's website, <http://www.trimedyne.com>.

### "Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.

\* \* \* \* \*